Current and emerging therapies for fungal biofilms and systemic infections

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Fungal infections represent a significant global health threat, exacerbated by increasing antifungal resistance.
• The limited arsenal of existing antifungal drugs (azoles, polyenes, echinocandins) and the protective nature of fungal biofilms present major therapeutic challenges.
• Fungal biofilms, characterized by an extracellular matrix, impede the efficacy of conventional antifungal treatments.

Purpose of the Study:

• To review the current landscape of antifungal resistance in human fungal pathogens.
• To emphasize emerging therapeutic strategies for combating fungal infections and biofilms.
• To explore novel treatments, repurposed drugs, and natural products as potential alternatives to conventional therapies.

Main Methods:

• Literature review of current research on antifungal resistance mechanisms.
• Analysis of emerging therapeutic approaches targeting fungal growth inhibition and biofilm disruption.
• Evaluation of novel treatments, repurposed drugs, and natural products for antifungal activity.

Main Results:

• Antifungal resistance is a critical issue driven by limited drug classes and biofilm formation.
• Numerous novel antifungal strategies are under development, including new drugs, drug repurposing, and natural product-based therapies.
• These emerging approaches show promise in inhibiting fungal growth, disrupting biofilms, and overcoming resistance.

Conclusions:

• Emerging therapeutics offer potential solutions to overcome antifungal resistance and biofilm challenges.
• Further research is needed to refine these novel approaches for clinical application.
• Innovative strategies are essential for developing more effective treatments for fungal infections and biofilm eradication.